Clinical trials: Early Alzheimers Disease
Alzheimer Disease, Dementia
A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)
The reason for this study is to assess the safety and efficacy of donanemab in participants with early Alzheimer's disease. The study duration including screening and follow-up is up to 93 weeks.
- Conditions
- Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases
- Trial name
- NCT05508789
- Testing
- Donanemab
- Where
- 141 sites in Argentina, Australia and 6 more
- Volunteers
- 1,500 people
- Sponsor
- Eli Lilly and Company
Alzheimer Disease, Early Onset
Neuronavigation-guided FUS-induced BBB Opening in Alzheimer's Disease Patients and Its Effects on Brain Amyloid and Tau
The primary purpose of this phase 1b study is to further assess the safety and reversibility of focused ultrasound induced blood-brain barrier opening (FUS-BBBO) in participants with Alzheimer´s Disease (AD) using a…
- Trial name
- FUS-AD (NCT06600880)
- Testing
- Neuronavigation-guided single-element focused ultrasound transducer, Lumason, Magnetic Resonance Imaging (MRI) with or without gadolinium contrast agents
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Columbia University
Alzheimer Disease, Hearing Loss
Early Age-Related Hearing Loss Investigation (EARHLI)
Early Age-Related Hearing Loss Investigation (EARHLI) is a single site study that will randomize late middle age adults to either a hearing intervention (including hearing aids) or a health education intervention.
- Conditions
- Alzheimer Disease, Hearing Loss, Cognitive Impairment
- Trial name
- EARHLI (NCT06174038)
- Testing
- Hearing Intervention, Health Education Intervention
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Columbia University
Alzheimer Disease
PDE5 Inhibitor for Alzheimer's Disease
Alzheimer's disease is the most common cause of dementia in the elderly population. The disease is characterised by the presence of abnormal proteins in the brain, primarily β-amyloid (Aβ) and tau.
- Trial name
- NCT07172815
- Testing
- tadalafil
- Volunteers
- 244 people
- Sponsor
- Imperial College London
Alzheimer Disease
A Multiple Dose Study of the Safety and Pharmacokinetics of NTRX-07
This is a Phase 1, Randomized, Placebo-Controlled, Modified Parallel Design Multiple Ascending Dose Study of NTRX 07 to Assess Safety and Tolerability and Pharmacokinetics in Adult Healthy Volunteers and Subjects with MCI or…
- Trial name
- NCT06194552
- Testing
- NTRX-07
- Where
- 2 sites in United States, Hungary
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- NeuroTherapia, Inc.
Alzheimer's Disease, Mild Cognitive Impairment
Korean Brain Aging Study for Early Diagnosis and Prediction of Alzheimer's Disease
This is a prospective cohort study for cognitively normal (young and old), mild cognitive impairment, and Alzheimer's disease people
- Trial name
- KBASE (NCT02137460)
- Where
- South Korea
- Volunteers
- 721 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Delirium, Cognitive Impairment
Illuminating Neuropsychological Dysfunction and Systemic Inflammatory Mechanisms Gleaned After Hospitalization in Trauma-ICU Study
Cognitive skills are essential to live independently, manage finances, maintain employment, and function in society. Loss of these cognitive skills puts a tremendous burden on society as seen with dementias, Alzheimer's disease…
- Conditions
- Delirium, Cognitive Impairment, Alzheimer; Early Onset, Trauma
- Trial name
- INSIGHT-ICU (NCT03098459)
- Testing
- Non-interventional observational prospective cohort study
- Where
- United States
- Volunteers
- 432 people
- Sponsor
- Vanderbilt University Medical Center
Alzheimer's Disease, Mild Cognitive Impairment
FluoroAv45 Imaging Research-in Alzheimer's Disease
Rationale: improving the early detection of AD at prodromal pre-dementia stages has become a major matter of concern. There is now an important body of literature stating that early isolated cognitive deficits (Mild Cognitive…
- Trial name
- FAIR-AD (NCT01325259)
- Testing
- neuropsychologic assessment, [18F]AV-45 PET, 18-FDG PET
- Where
- 4 sites in France
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- University Hospital, Tours
Early Alzheimer's Disease
An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD Subjects
This study is being conducted to evaluate the safety and efficacy of ALZ-801 in Early Alzheimer's disease (AD) subjects with the APOE4/4 genotype.
- Trial name
- APOLLOE4 (NCT04770220)
- Testing
- Experimental: ALZ-801
- Where
- 95 sites in United States, Canada and 7 more
- Volunteers
- 325 people
- Sponsor
- Alzheon Inc.
Multiple Myeloma
Detecting Early Myocardial Infiltration w/Amyloid & Light Chain Deposition Disease in Multiple Myeloma Subjects
The purpose of this study is to see if MRI techniques can be used for early evaluation of cardiac amyloidosis which is sometimes seen in individuals with multiple myeloma.
- Trial name
- NCT01018927
- Testing
- Administering three additional MRI images
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- University of Arkansas
Alzheimers Disease
A Postmarketing Study of LEQEMBI in Participants With Alzheimer's Disease
The primary purpose of this study is to evaluate the efficacy of LEQEMBI in participants with early Alzheimer's disease (AD) indicated per Canada Product Monograph (APOE4 non-carriers and heterozygotes; indicated population)…
- Trial name
- NCT07864623
- Testing
- No Intervention
- Where
- United States
- Volunteers
- 270 people
- Sponsor
- Eisai Inc.
Mild Cognitive Impairment (MCI), Alzheimer Disease
A Study of Donanemab (LY3002813) Compared With Aducanumab in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 4)
The main purpose of this study is to compare donanemab to aducanumab on brain amyloid plaque clearance in participants with early symptomatic Alzheimer's Disease (AD).
- Trial name
- NCT05108922
- Testing
- Donanemab, Aducanumab
- Where
- 31 sites in United States
- Volunteers
- 148 people
- Sponsor
- Eli Lilly and Company
Mild Dementia, Mild Cognitive Impairment
The Swedish BioFINDER - Primary Care Study
The overall aim of the study is to improve the diagnostic accuracy of AD and cognitive impairment in primary care settings to ensure better care and treatment as well as facilitate correct referrals to specialized memory clinics.
- Conditions
- Mild Dementia, Mild Cognitive Impairment, SCD, Alzheimer Disease
- Trial name
- ADetect (NCT06120361)
- Testing
- Plasma APS 2 score, Plasma p-tau217/np-tau217, Plasma p-tau217
- Where
- Sweden
- Volunteers
- 1,200 people
- Sponsor
- Skane University Hospital
Alzheimer Disease, Mild Cognitive Impairment
Phenserine on the Alzheimer's Treatment Horizon, Study 1
The goal of this clinical trial is to evaluate if phenserine can treat early or mild Alzheimer's Disease (AD) by comparing it to donepezil.
- Trial name
- PATH-1 (NCT06774261)
- Testing
- Phenserine, Donepezil (Aricept®)
- Where
- Norway
- Volunteers
- 16 people
- Sponsor
- Helse Stavanger HF
Alzheimer's Disease, Cognitive Impairment
A Study to Evaluate the Safety, Tolerability and Immunogenicity of Tau Targeted Vaccines in Participants With Early Alzheimer's Disease
This study is a multicenter, double blind, randomized, placebo-controlled study to evaluate the safety, tolerability and immunogenicity of different doses, regimens and combinations of Tau targeted vaccines in participants with…
- Conditions
- Alzheimer's Disease, Cognitive Impairment, Tauopathies, Mild Cognitive Impairment
- Trial name
- NCT04445831
- Testing
- ACI-35.030, JACI-35.054
- Where
- 9 sites in Finland, Netherlands and 2 more
- Volunteers
- 57 people
- Sponsor
- AC Immune SA
Dementia, Alzheimer Disease
Integrating eSAGE With EHR Data Using Machine Learning for the Early Detection and Monitoring of Cognitive Impairment in Individuals
The goal of this observational trial is to leverage the electronic Self-Administered Gerocognitive Examination (eSAGE), a variety of metadata (a set of data that describes and gives information about other data) collected during…
- Conditions
- Dementia, Alzheimer Disease, Mild Cognitive Impairment, Worried Well
- Trial name
- NCT06017505
- Testing
- electronic self administered gerocognitive examination (eSAGE)
- Where
- United States
- Volunteers
- 1,486 people
- Sponsor
- Douglas Scharre
Mild Cognitive Impairment, Alzheimer's Disease
The Swedish BioFINDER Study
The present study aims at combining biochemical methods with various types of imaging techniques to identify the pathophysiology of Alzheimer's disease (AD).
- Conditions
- Mild Cognitive Impairment, Alzheimer's Disease, Dementia With Lewy Bodies, Vascular Dementia
- Trial name
- NCT01208675
- Where
- 2 sites in Sweden
- Volunteers
- 1,150 people, healthy volunteers welcome
- Sponsor
- Skane University Hospital
Mild Cognitive Impairment, Biomarker
Early Diagnosis and Early Treatment of Alzheimer's Disease Based on Senile Plaque Imaging
The purpose of this study is based on the Flutemetamol-PET senile plaque imaging to investigate the peripheral blood biochemical and brain MRI imaging biomarkers and to research completely independent intellectual property rights…
- Conditions
- Mild Cognitive Impairment, Biomarker, Diagnosis, Treatment
- Trial name
- NCT02931136
- Testing
- Huperzine A
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Shanghai Mental Health Center
Cognitive Decline, Mild, Alzheimer Disease
Fasudil Trial for Treatment of Early Alzheimer's Disease (FEAD)
The goal of this placebo-controlled double-blind Phase 2 clinical trial is to test in people with early Alzheimer's Disease. The main questions it aims to answer are: Does treatment with fasudil, a ROCK-inhibitor, lead to…
- Trial name
- FEAD (NCT06362707)
- Testing
- Fasudil
- Where
- 6 sites in Norway
- Volunteers
- 200 people
- Sponsor
- Helse Stavanger HF
Alzheimer's Disease
A Post Marketing Study in Participants With Early Alzheimer's Disease Treated With Lecanemab
The primary purpose of this study is to investigate the characteristics of amyloid related imaging abnormalities (ARIA) and investigate the treatment continuation status (e.g., continuation, interruption) after the onset of ARIA…
- Trial name
- NCT06322667
- Testing
- No Intervention
- Where
- 3 sites in Japan
- Volunteers
- 5,000 people
- Sponsor
- Eisai Co., Ltd.